Comparative effectiveness of combined therapy inhibiting EGFR and VEGF pathways in patients with advanced non-small-cell lung cancer: a meta-analysis of 16 phase II/III randomized trials

BACKGROUND & AIMS: Combined therapy inhibiting EGFR and VEGF pathways is becoming a promising therapy in the treatment of advanced non-small-cell lung cancer (NSCLC), however, with controversy. The study aims to compare the efficacy of combined inhibition therapy versus control therapy (includin...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yongzhao, Wang, Huixian, Shi, Yan, Cai, Shangli, Wu, Tongwei, Yan, Guangyue, Cheng, Sijin, Cui, Kang, Xi, Ying, Qi, Xiaolong, Zhang, Jie, Ma, Wang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351687/
https://www.ncbi.nlm.nih.gov/pubmed/27690345
http://dx.doi.org/10.18632/oncotarget.12294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351687/
https://www.ncbi.nlm.nih.gov/pubmed/27690345
http://dx.doi.org/10.18632/oncotarget.12294

Ejemplares similares